2021 IDEAs Award Winners Give Hope for Stroke and Heart Attack Victims
October 6, 2021
Recent UAF biomedical research found that drugs may be used to control the metabolic rate in humans after cardiac arrest and stroke to improve survival and neurological outcomes. This groundbreaking research won the 2021 top IDEAs award.
The Innovative Disclosures and Entrepreneurial Activities (IDEAs) awards, hosted by the UAF Office of Intellectual Property and Commercialization, recognize innovative solutions from invention disclosures submitted from UAF and UAS for the academic year.
Researchers Kelly Drew and Bernard Laughlin of UAF鈥檚 Institute of Arctic Biology and Department of Chemistry and Biochemistry won the award for their disclosure entitled 鈥淎nticholinergic Formulation and Method.鈥
In critical care medicine, patients are exposed to cold during targeted temperature management, now the general standard of care following cardiac arrest. However, exposure to cold stimulates metabolism and interferes with the therapeutic efficacy of targeted temperature management.
The inventors have discovered unexpected synergism by utilizing pharmaceutical formulations including three drug classes. The combination of the three drug classes show synergy in their effects on metabolic rate, heart rate, and blood pressure, to allow for more precise control of metabolic rate and core body temperature.
This innovation has been submitted as a U.S. provisional patent application through OIPC. The research was supported by the National Institutes of Health.
The IDEAs award winners were announced during an in-person and virtual September 28 ICE Jam innovation and entrepreneurship event in partnership with UAF Climate Scholars Program and Honors College. All IDEAs winners were recognize